| Chemical Properties | Back Directory | [Sequence]
His-Gly-Glu-Gly-Ser-Phe-Ser-Ser-Glu-Leu-Ser-Thr-Ile-Leu-Asp-Ala-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Ala-Trp-Leu-Ile-Ala-Thr-Lys-Ile-Thr-Asp-Lys-Lys-Lys-Lys-Lys-Lys-NH2 |
| Hazard Information | Back Directory | [Uses]
Elsiglutide (ZP1846) is a GLP-2 analogue, an orally active and selective GLP-2 receptor agonist, increases cell proliferation and reduces apoptosis in the intestine. Elsiglutide improves Lapatinib.html" class="link-product" target="_blank">Lapatinib (HY-50898)-induced diarrhoea in rat model[1][2]. | [in vivo]
Elsiglutide (500 mg/kg; p.o.; once daily; 4 times per week for 4 weeks) reduces the most severe diarrhoea seen from Lapatinib (500 mg/kg; p.o.) in rat model[1].
| Animal Model: | Male Albino Wistar rats (250-280 g)[1] | | Dosage: | 500 mg/kg, with or not 500 mg/kg Lapatinib | | Administration: | Oral gavage; once daily, 4 non-consecutive days per week with vehicle solution being administered on the other 3 days for 4 weeks | | Result: | Resulted less?incidence of?diarrhoea compared to?lapatinib alone.
Signifcantly less weight gain from day 7 of treatment compared to control. |
| [References]
[1] Mayo BJ, et al. The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats. Cancer Chemother Pharmacol. 2020 Apr;85(4):793-803. DOI:10.1007/s00280-020-04040-0
[2] Mayo B, et al. The new selective glp-2 receptor agonist, elsiglutide, improves irinotecan-induced diarrhoea and mucositis in the rat. Asia Pacific Journal of Clinical Oncology, 2014, vol.10, iss.Suppl. 8, pp.134-134. |
|
| Company Name: |
YantaiBio
|
| Tel: |
13758194781 15083780366 |
| Website: |
|
|